Ivosidenib is a targeted therapeutic drug for adult patients with relapsed or refractory acute myeloid leukemia (AML) who carry IDH1 mutations. This article will comprehensively introduce relevant information about Ivosidenib from three aspects: domestic price, medication guidance, and precautions for use, to help patients and their families gain a better understanding of this drug.

Domestic Price of Ivosidenib

Ivosidenib is an imported drug, and its price is one of the key concerns for patients. Currently, the drug has been launched in China but has not yet been included in medical insurance, so patients need to purchase it at their own expense. Understanding its price and purchasing channels helps patients make rational choices.

Price and Specifications

The price of the original brand of Ivosidenib is relatively high, while there are also multiple generic versions available on the market. For example, the generic version produced by Lucius (Laos) has a specification of 250mg*60 tablets, with a price of approximately 1,206 US dollars per box; the similar product from Everest Pharmaceuticals (Bangladesh) is priced at around 1,165 US dollars per box. Patients can choose a suitable version based on their own economic conditions and doctors' recommendations.

Purchasing Channels

Patients can purchase Ivosidenib through hospitals, online pharmacies, formal medical service institutions, or cross-border e-commerce platforms. When purchasing, it is necessary to carefully identify the authenticity of the drug, check the production date and the integrity of the packaging, avoid buying counterfeit or substandard drugs, and ensure medication safety.

The price and purchasing channels of Ivosidenib directly affect patients' treatment choices. While understanding price information, patients should also pay attention to the quality and source of the drug to lay a solid foundation for subsequent treatment.

Medication Guidance for Ivosidenib

The correct medication method is crucial to ensuring the efficacy of Ivosidenib. The following provides detailed medication guidance for patients from two aspects: dosage and administration, and toxicity monitoring.

Dosage and Administration

The recommended dose of Ivosidenib is 500mg, taken orally once daily, until disease progression or unacceptable toxicity occurs. The drug can be taken on an empty stomach or after meals, but high-fat foods should be avoided. If a dose is missed or vomiting occurs after taking the drug, there is no need to make up for the missed dose; continue taking the drug at the originally scheduled time. In addition, the tablets must not be split or crushed for administration.

Toxicity Monitoring

During treatment, it is necessary to regularly check indicators such as blood cell count, blood biochemistry, and electrocardiogram. Frequent monitoring is required before the first dose administration and in the early stage of treatment, and the frequency can be appropriately reduced in the later stage. If abnormalities occur, the dose should be adjusted in a timely manner or medication should be suspended, and a doctor should be consulted.

Following scientific medication guidance can maximize the efficacy of Ivosidenib while reducing the occurrence of adverse reactions. Patients should strictly follow the doctor's advice and ensure compliance with medication standards.

Precautions for Using Ivosidenib

There may be certain risks during the use of Ivosidenib. Understanding the relevant precautions helps patients take preventive measures in advance and maintain medication safety.

Adverse Reactions

Common adverse reactions include fatigue, joint pain, diarrhea, nausea, etc. If severe reactions such as differentiation syndrome, QT interval prolongation, or Guillain-Barré syndrome occur, immediate medical attention is required, and medication may need to be suspended or discontinued if necessary.

Medication for Special Populations

Pregnant women, lactating women, children, and patients with hepatic or renal insufficiency should use Ivosidenib with caution. Elderly patients do not need dose adjustment, but patients with severe hepatic or renal impairment should decide whether to use the drug only after a doctor evaluates the risks and benefits.

Precautions for medication are an important guarantee for patients' safe medication. By understanding adverse reactions and medication restrictions for special populations, patients can better avoid risks and ensure the smooth progress of treatment.